Subsequent Chemotherapy and Treatment Patterns After Abiraterone Acetate in Patients with Metastatic Castration-resistant Prostate Cancer: Post Hoc Analysis of COU-AA-302

BACKGROUND: Treatment patterns for metastatic castration-resistant prostate cancer (mCRPC) have changed substantially in the last few years. In trial COU-AA-302 (chemotherapy-naïve men with mCRPC), abiraterone acetate plus prednisone (AA) significantly improved radiographic progression-free survival...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:Eur Urol
Autori principali: de Bono, Johann S., Smith, Matthew R., Saad, Fred, Rathkopf, Dana E., Mulders, Peter F.A., Small, Eric J., Shore, Neal D., Fizazi, Karim, De Porre, Peter, Kheoh, Thian, Li, Jinhui, Todd, Mary B., Ryan, Charles J., Flaig, Thomas W.
Natura: Artigo
Lingua:Inglês
Pubblicazione: 2016
Soggetti:
Article
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC5609503/
https://ncbi.nlm.nih.gov/pubmed/27402060
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.eururo.2016.06.033
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi